Miransertib
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Trial Timeline
Nov 2, 2021 → Feb 7, 2030
NCT ID
NCT04980872About Miransertib
Miransertib is a phase 2 stage product being developed by Merck for PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS). The current trial status is active. This product is registered under clinical trial identifier NCT04980872. Target conditions include PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS).
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04980872 | Phase 2 | Active |
| NCT03094832 | Phase 1/2 | Terminated |
Competing Products
6 competing products in PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 1/2 | 24 |
| Alpelisib | Novartis | Phase 2 | 42 |
| Alpelisib | Novartis | Phase 2 | 39 |
| Alpelisib + Placebo | Novartis | Phase 2 | 39 |
| alpelisib | Novartis | Pre-clinical | 30 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 36 |